The invention relates to a process for the preparation of the pharmaceutically applicable methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate hydrogen sulphate (also known as S-(+)-clopidogrel hydrogen sulphate) of formula (I) comprising racemizing methyl (R)-(-)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine- 5(4H)-acetate or methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate, or a mixture thereof in any proportion with a weak base in the presence of an organic solvent, converting the methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5(4H)-acetate of fomula (II) obtained to its sulphuric acid addition salt methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulphate and converting it to methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c] pyridine-5(4H)-acetate hydrogen sulphate of formula (I) by known manner.
该发明涉及一种制备药用可应用的甲基(S)-(+)-α-(2-
氯苯基)-6,7-二氢
噻吩[3,2-c]
吡啶-5(4H)-
醋酸氢硫酸盐(也称为S-(+)-
氯吡格雷醋酸氢硫酸盐)的过程,包括在有机溶剂的存在下,使用弱碱将甲基(R)-(-)-α-(2-
氯苯基)-6,7-二氢
噻吩[3,2-c]
吡啶-5(4H)-
醋酸酯或甲基(S)-(+)-α-(2-
氯苯基)-6,7-二氢
噻吩[3,2-c]
吡啶-5(4H)-
醋酸酯,或两者的任意比例混合物进行消旋,将得到的甲基(R,S)-(±)-α-(2-
氯苯基)-6,7-二氢
噻吩[3,2-c]
吡啶-5(4H)-
醋酸酯(式II)转化为其
硫酸加合物盐甲基(R,S)-(±)-α-(2-
氯苯基)-6,7-二氢
噻吩[3,2-c]
吡啶-5(4H)-
醋酸氢硫酸盐,并通过已知方法将其转化为甲基(S)-(+)-α-(2-
氯苯基)-6,7-二氢
噻吩[3,2-c]
吡啶-5(4H)-
醋酸氢硫酸盐(式I)。